Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02009449 · OUTCOME

Pharmacokinetic (PK): Serum Concentration of Pegilodecakin

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors · Source last updated 2026-07-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
nanogram per milliliter (ng/mL)
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Day 29

What was measured

Serum concentration of Pegilodecakin is reported.

Analysis population: Participants who received at least one dose of the study intervention and had evaluable PK data. Per protocol, PK data was pre-specified to be analyzed by Pegilodecakin dose levels across all parts.

Groups in this outcome

Pegilodecakin 0.08/0.1 mg

Participants who received 0.08 or 0.1 mg of Pegilodecakin once QD administered SC across all parts are grouped under this arm.

Pegilodecakin 0.2/0.25 mg

Participants who received 0.2 or 0.25 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.

Pegilodecakin 0.4/0.5 mg

Participants who received 0.4 or 0.5 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.

Pegilodecakin 0.8/1 mg

Participants who received 0.8 or 1 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.

Pegilodecakin 1.6/2 mg

Participants who received 1.6 or 2 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.

Pegilodecakin 3.2/4 mg

Participants who received 3.2 or 4 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pegilodecakin 0.08/0.1 mg4
Pegilodecakin 0.2/0.25 mg11
Pegilodecakin 0.4/0.5 mg11
Pegilodecakin 0.8/1 mg9
Pegilodecakin 1.6/2 mg31
Pegilodecakin 3.2/4 mg2

Reported measurements

Source class 1
Values in nanogram per milliliter (ng/mL) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Pegilodecakin 0.08/0.1 mg1.36172Not reportedNot reportedNot reported
Pegilodecakin 0.2/0.25 mg1.3359Not reportedNot reportedNot reported
Pegilodecakin 0.4/0.5 mg3.3361Not reportedNot reportedNot reported
Pegilodecakin 0.8/1 mg7.3293Not reportedNot reportedNot reported
Pegilodecakin 1.6/2 mg25.475Not reportedNot reportedNot reported
Pegilodecakin 3.2/4 mg33.226Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        172
        value
        1.36
      2. group Id
        OG001
        spread
        59
        value
        1.33
      3. group Id
        OG002
        spread
        61
        value
        3.33
      4. group Id
        OG003
        spread
        93
        value
        7.32
      5. group Id
        OG004
        spread
        75
        value
        25.4
      6. group Id
        OG005
        spread
        26
        value
        33.2
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      11
    3. group Id
      OG002
      value
      11
    4. group Id
      OG003
      value
      9
    5. group Id
      OG004
      value
      31
    6. group Id
      OG005
      value
      2
    units
    Participants
description
Serum concentration of Pegilodecakin is reported.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants who received 0.08 or 0.1 mg of Pegilodecakin once QD administered SC across all parts are grouped under this arm.
    id
    OG000
    title
    Pegilodecakin 0.08/0.1 mg
  2. description
    Participants who received 0.2 or 0.25 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.
    id
    OG001
    title
    Pegilodecakin 0.2/0.25 mg
  3. description
    Participants who received 0.4 or 0.5 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.
    id
    OG002
    title
    Pegilodecakin 0.4/0.5 mg
  4. description
    Participants who received 0.8 or 1 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.
    id
    OG003
    title
    Pegilodecakin 0.8/1 mg
  5. description
    Participants who received 1.6 or 2 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.
    id
    OG004
    title
    Pegilodecakin 1.6/2 mg
  6. description
    Participants who received 3.2 or 4 mg of Pegilodecakin QD administered SC across all parts are grouped under this arm.
    id
    OG005
    title
    Pegilodecakin 3.2/4 mg
param Type
GEOMETRIC_MEAN
population Description
Participants who received at least one dose of the study intervention and had evaluable PK data. Per protocol, PK data was pre-specified to be analyzed by Pegilodecakin dose levels across all parts.
reporting Status
POSTED
time Frame
Day 29
title
Pharmacokinetic (PK): Serum Concentration of Pegilodecakin
type
PRIMARY
unit Of Measure
nanogram per milliliter (ng/mL)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice